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Modulation of PKM alternative splicing by PTBP1 promotes
gemcitabine resistance in pancreatic cancer cells
S Calabretta1,2, P Bielli3, I Passacantilli1,2, E Pilozzi4, V Fendrich5, G Capurso2, G Delle Fave2 and C Sette1,3
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons,
including acquisition of resistance to gemcitabine, the first-line chemotherapeutic approach. Thus, there is a strong need for novel
therapies, targeting more directly the molecular aberrations of this disease. We found that chronic exposure of PDAC cells to
gemcitabine selected a subpopulation of cells that are drug-resistant (DR-PDAC cells). Importantly, alternative splicing (AS) of the
pyruvate kinase gene (PKM) was differentially modulated in DR-PDAC cells, resulting in promotion of the cancer-related PKM2
isoform, whose high expression also correlated with shorter recurrence-free survival in PDAC patients. Switching PKM splicing by
antisense oligonucleotides to favor the alternative PKM1 variant rescued sensitivity of DR-PDAC cells to gemcitabine and cisplatin,
suggesting that PKM2 expression is required to withstand drug-induced genotoxic stress. Mechanistically, upregulation of the
polypyrimidine-tract binding protein (PTBP1), a key modulator of PKM splicing, correlated with PKM2 expression in DR-PDAC cell
lines. PTBP1 was recruited more efficiently to PKM pre-mRNA in DR- than in parental PDAC cells. Accordingly, knockdown of PTBP1
in DR-PDAC cells reduced its recruitment to the PKM pre-mRNA, promoted splicing of the PKM1 variant and abolished drug
resistance. Thus, chronic exposure to gemcitabine leads to upregulation of PTBP1 and modulation of PKM AS in PDAC cells,
conferring resistance to the drug. These findings point to PKM2 and PTBP1 as new potential therapeutic targets to improve
response of PDAC to chemotherapy.
Oncogene advance online publication, 3 August 2015; doi:10.1038/onc.2015.270
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of the most
aggressive human cancers, being characterized by very low 5-year
survival rate.1 Lack of early symptoms and late diagnosis
contribute to poor prognosis, with most patients presenting with
metastasis. When surgical resection is unfeasible, chemotherapy
with gemcitabine, administered either alone or in combination
with other compounds, represents the clinical option for PDAC.
Nevertheless, relapse always occurs with more aggressive features
and insensitivity to chemotherapy, contributing to high lethality.2,3
Thus, identification of new diagnostic markers and elucidation of
the molecular pathways involved in acquisition of drug resistance
represent clinical priorities for PDAC.2,4
Adaptation to variable stresses is a key feature of neoplastic
cells. Recent evidence highlighted how cancer cells can flexibly
modulate gene expression at the level of alternative splicing (AS)
to withstand hostile conditions.5–8 In this regard, changes in
expression of some splicing factors have been directly linked to
expression of oncogenic splice variants that confer various
advantages to cancer cells.9–14 Moreover, genotoxic stress was
shown to modulate splicing regulation,15 in some cases by
affecting the localization or activity of specific splicing factors,
such as SAM68(ref. 16) or EWS.17 In the case of PDAC cells, it was
previously shown that increased expression of the serine/arginine-
rich protein kinase SRPK1, a prototypic splicing factor kinase,
confers resistance to treatment with gemcitabine.18 Notably, as
SRPK1 modulates the activity of several serine/arginine protein
splicing factors with implication in cancer,19 including SRSF1,20 it is
likely that upregulation of this kinase contributes to the
expression of oncogenic splice variants expressed in PDAC
cells.21
Herein, we aimed at investigating the role of AS and splicing
factors in the acquisition of a drug-resistant (DR) phenotype in
PDAC cells. We observed that chronic treatment with gemcitabine
promoted the formation of DR subpopulations highly resistant
to drug-induced genotoxic stress. In order to understand the
contribution of AS to the DR phenotype, we analyzed a group of
cancer-related splice variants involved in oncogenic features.5–8
We found that DR-PDAC cells exhibited a switch in PKM AS, a gene
encoding two alternative splice variants, PKM1 and PKM2, through
usage of mutually exclusive exons. PKM2 is typically expressed in
cancer cells where it confers oncogenic features.22–24 We show
that splicing of PKM2 is favored in DR-PDAC cells with respect to
the parental cells and promotes drug resistance, as interference
with this splicing event in DR-PDAC cells restored sensitivity to
gemcitabine and cisplatin. Mechanistically, we demonstrate that
the polypyrimidine-tract binding protein PTBP1 is upregulated in
DR-PDAC cells, and that its increased recruitment to the PKM pre-
mRNA promotes PKM2 splicing. Knockdown of PTBP1 in DR-PDAC
cells reduces its binding to PKM pre-mRNA, favors the expression
of PKM1 and rescues drug sensitivity. Hence, our results indicate a
positive role for PTBP1 and PKM2 in the acquisition of drug
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resistance, suggesting that this regulatory pathway represents a
novel potential therapeutic target for PDAC.
RESULTS
Isolation of DR-PDAC cells
To isolate DR-PDAC cell sub-populations, we exposed to chronic
treatment with gemcitabine (10 μM) the following two cell lines:
Pt45P1, which displays higher sensitivity to the drug, and PANC-1,
which is more resistant to treatment (Supplementary Figure S1A).
As expected, gemcitabine caused massive cell death in both cell
lines in the 7 days of treatment. However, 15 days after removal of
the drug, few viable clones were visible in the plates of both cell
lines. Clones were pooled, amplified and cultured by exposing
them to a 24-h pulse of gemcitabine every other week, to
maintain selection of the DR populations (Figures 1a and b).
To confirm that DR-PDAC cells were indeed more resistant to
drug treatment than the parental cell line (PCL), we analyzed cell
survival by colony formation assays. PCL- and DR-PDAC cells were
cultured for 24 h with sub-optimal doses of gemcitabine and then
allowed to grow in complete medium until they formed visible
colonies (Figures 1c and d). Treatment with gemcitabine reduced
the number of colonies in a dose-dependent manner in PCL cells,
whereas DR cells were resistant to the lower dose of gemcitabine
and less sensitive to the higher dose (Figures 1c and d). Analysis of
cell death by Trypan blue cell count or by immunofluorescence
analysis of the cleaved/activated form of caspase-3 confirmed that
gemcitabine was more cytotoxic for PCL- than DR-PDAC cells
(Supplementary Figures S1B and C). Collectively, these results
indicate that the selected cell populations have acquired a DR
phenotype.
PKM splicing is regulated in DR-PDAC cells
Recent evidence suggests a key role for misregulation of AS in the
acquisition of oncogenic features and drug resistance by human
cancer cells.5–8 Thus, we tested whether PCL- and DR-PDAC cells
display changes in splice variants of a subset of cancer-relevant
genes. We selected a group of genes whose AS was reported to
promote oncogenic features in cancer cells, such as the apoptotic
genes CASP9,25 CASP2,26 BCL-X,27 BIM28 and FAS29 (Figure 2a and
Supplementary Figure 2A); genes involved in DNA repair and drug
resistance, such as USP5(ref. 30) and MKNK2(refs 31,32) (Figure 2b and
Supplementary Figure 2B); genes affecting basal metabolism, such
as PKM22 (Figure 2c); genes involved in cell migration and
invasion, such as RON10, CD44(ref. 5) and c-MET33 (Figure 2d and
Supplementary Figure 2C); or the cell cycle gene CCND1(ref. 34)
(Figure 2e). Reverse transcription–PCR (RT–PCR) analysis showed
that AS of most of these genes was either unchanged between
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Figure 1. Chronic treatment with gemcitabine selects DR-PDAC cells. (a) Schematic representation of the protocol used to obtain DR-PDAC
cells from parental PDAC cells (PCL). (b) Representative phase-contrast images of PCL- and DR-Pt45P1 (left panels) or PANC-1 (right panels)
cells (×40 magnification). Representative images of the colony assay (upper panels) performed in PCL- and DR-Pt45P1 (c) or PANC-1 cells (d).
(c and d) Bar graphs (bottom panels) show the percentage of survival with respect to untreated cells from three experiments (mean± s.d.), as
assessed by colony formation. Brackets indicate statistical comparison of the indicated samples. Statistical analyses were performed by the
paired Student’s t-test. **P⩽ 0.01.
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PCL- and DR-PDAC cells (CASP2, CCND1, c-MET, USP5, MKNK2 and
RON) or not modulated in the same direction in DR-PDAC cell lines
(CASP9, BCL-X, BIM, CD44 and FAS) (Figure 2 and Supplementary
Figure 2). On the contrary, splicing of the PKM2 variant was
favored with respect to PKM1 in both DR-PDAC cell lines
(Figure 2c), suggesting that modulation of PKM AS correlated
with acquisition of drug resistance in PDAC cells.
PKM2 protein is upregulated in DR-PDAC cells and correlates with
relapse-free survival in PDAC patients
We focused on the regulation of PKM AS, because growing
evidence supports a key role for this splicing event in
tumorigenesis.22,35 The PKM2 splice variant is prevalently
expressed in cancer cells,22,36 where it regulates processes
spanning from cell metabolism22,24 to transcription,23 cell cycle37
and cell death.38,39 Differential expression of PKM1 and PKM2 in
DR-PDAC cells was confirmed by RT–PCR analysis using primers
positioned either in exon 9 (PKM1) or 10 (PKM2), to amplify each
splice variant (Figure 3a). Furthermore, the switch in PKM splice
variants was confirmed at the protein level, as DR-PDAC
cells expressed higher levels of PKM2, whereas PKM1 was
almost undetectable with respect to PCL-PDAC cells (Figure 3b).
Notably, PANC-1 cells, which are more resistant to gemcitabine
(Supplementary Figure S1A), also express higher levels of
PKM2 and lower levels of PKM1 than the more sensitive
Pt45P1 cells (Figure 3c). These observations indicate that the
DR phenotype of PDAC cells correlates with increased expres-
sion of PKM2.
To assess the relevance of PKM2 in vivo, we investigated its
expression levels by immunohistochemistry (IHC) in a cohort
of 42 patients diagnosed with primary PDAC in the absence of
metastases, who received radical surgery and subsequent
gemcitabine-based adjuvant treatment. Our hypothesis was
that patients expressing high levels of PKM2 could be more
resistant to gemcitabine and display worse clinical outcome. The
anti-PKM2 antibody was validated by immunofluorescence and
western blot analyses of PANC-1 cells silenced for PKM2 and
with mouse tissues expressing (embryonic) or not (adult)
PKM2 (Supplementary Figures S3A–C). Titration analysis estab-
lished 1:1600 as the optimal dilution for IHC (Supplementary
Figure S3D). The neoplastic lesions of all 42 samples (100%)
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Figure 2. The PKM2 splice variant is promoted in DR-PDAC cells. (a–e) RT–PCR analysis in PCL- and DR-Pt45P1 or PANC-1 cells of splice
variants encoded by the indicated cancer-related genes. Schematic representation of the cancer-related AS events analyzed is shown in the
upper panels. Exons (boxes) and introns (lines) are indicated. Black arrows indicate primers used for the RT–PCR analysis (bottom panels).
(c) RT–PCRs of PKM gene were followed by PstI digestion in order to distinguish the amplicons. Bar graphs represent the percentage of the
indicated AS variants, as assessed by densitometric analysis of the bands. Statistical analyses were performed by the paired Student’s t-test
comparing PCL- and DR-PDAC cell values (mean± s.d., n= 3, **Po0.01; ns, not significant). (f) HPRT was used as loading control for RT–PCR
analyses in a–e.
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showed cytoplasmic PKM2 staining (Figure 3d), whereas non-
neoplastic pancreatic tissue occasionally displayed very weak
PKM2 staining in normal ductal and acinar cells (Supplementary
Figure S3D). A linear score of staining (range 0–5) was assigned to
each sample (see Materials and Methods) and patients were
subdivided in two groups: the ‘low PKM2’ group comprised 16
samples characterized by weak PKM2 staining (that is, ⩽ 3)
(Figure 3d, upper panels), whereas the ‘high PKM2’ group
comprised 26 samples displaying stronger PKM2 staining (that
is,43) (Figure 3d, lower panels). No differences regarding age, sex
and pathological features (mean tumor size, grade, stage and
resection margins) were found between the two groups
(Supplementary Table S1). However, the recurrence free survival
(RFS), defined as the time elapsing from surgery to disease
recurrence, was significantly shorter in patients with ‘high PKM2’
(mean 11.6 months) as compared with the ‘low PKM2’ group
(mean 19.8 months, P= 0.04; Supplementary Table S1). Accord-
ingly, RFS estimated by the Kaplan–Meier curve was significantly
shorter in the first group (Figure 3e) and PKM2 was the only risk
factor significantly associated with shorter RFS at a Cox
proportional-hazards regression (hazard ratio: 1.12; 95% confi-
dence interval: 1–4.4, P= 0.04). These data suggest that tumors
with higher PKM2 basal expression display more aggressive
behavior and worse response to chemotherapy.
Modulation of PKM splicing impairs drug resistance of
DR-PDAC cells
AS can be modulated in live cells by antisense short oligonucleo-
tides (ASOs) directed against a specific regulatory region.40 In the
case of PKM, an ASO targeting exon 10 could efficiently induce
splicing of PKM1 at the expense of PKM2.38 We used this tool to
modulate PKM splicing in PDAC cells and to evaluate the
contribution of PKM2 to the DR phenotype. RT–PCR and western
blot analyses indicated that AS of endogenous PKM could be
efficiently modulated by transfection of the ASO in PDAC cells
(Figures 4a and b). Analysis of cell death by immunofluorescence
for the cleaved/activated form of caspase-3 (Figure 4c) showed
that ASO-mediated switching of PKM AS in favor of PKM1
increased the sensitivity of DR-PDAC cells to gemcitabine without
affecting the basal level of cell death (Figure 4c). Furthermore,
overexpression of PKM2 in PCL-PDAC cells protected them from
gemcitabine-induced cell death (Supplementary Figures S4A and B).
These results indicate that PKM2 expression in DR-PDAC cells is
required to maintain gemcitabine resistance.
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Figure 3. PKM2 protein expression in PDAC cells and PDAC tissues. RT–PCR (a) and western blot (b) analyses of PKM1 and PKM2 splicing
variants in PCL- and DR-PDAC cells. Schematic representation of the PKM gene is shown in the upper panel; black arrows indicate the specific
primers used to amplify the PKM1 and PKM2 in PCL- and DR-PDAC cells. HPRT and PKM exon 5–6 regions were used as loading control (a).
Coomassie staining was used as loading control (b). (c) Western blot analysis of PKM1 and PKM2 protein in PCL-PDAC cells. Coomassie staining
was used as loading control. (d) Representative images of PKM2 immunohistochemistry in PDAC tissues (×10 magnification). Upper panels
show neoplastic glands with weak staining (low PKM2 group; score ⩽ 3); bottom panels show neoplastic glands with strong staining (high
PKM2; group score43). (e) Analysis of RFS of PDAC patients. Low PKM2 group comprised 16 patients (continuous line), whereas high PKM2
group comprised 26 patients (dotted line); P= 0.04 at log-rank test.
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PTBP1 is upregulated in DR-PDAC cells
Three hnRNPs (hnRNPI/PTBP1, hnRNPA2/B1 and hnRNPA1) were
shown to cooperate to suppress exon 9 inclusions in the PKM
transcript, leading to exon 10 inclusion and expression of the
PKM2 variant.35 Notably, these splicing factors were upregulated
in brain tumors and their expression strongly correlated with that
of PKM2.35 Thus, we investigated whether the expression of these
hnRNPs was altered in DR-PDAC cells with respect to PCL cells. We
found that only PTBP1 was markedly upregulated in both
DR-Pt45P1 and DR-PANC-1 cells (Figures 5a and b). The highly
homologous PTBP2 protein was not detected in PDAC cells
(Figures 5a and b). By contrast, hnRNPA2/B1 levels were
unchanged in PCL- and DR-PDAC cells, whereas hnRNPA1 was
upregulated in DR-PANC-1 (Figure 5b) but slightly reduced in
DR-Pt45P1 (Figure 5a). Furthermore, PTBP1 expression correlated
with sensitivity of PDAC cells to gemcitabine, as it was higher in
PANC-1 cells than in Pt45P1 cells (Supplementary Figure S5A). The
correlation between PTBP1 expression and PKM2 splicing in both
DR-PDAC cell lines was specific, as demonstrated by western blot
analysis of other cancer-related serine/arginine proteins and
hnRNPs in PCL- and DR-PDAC cells, which showed either marginal
or inconstant alterations. For instance, upregulation of SRSF1 was
detected in DR-Pt45P1 cells but not in DR-PANC-1 cells
(Supplementary Figure S5B), possibly because PANC-1 cells are
more resistant to drug treatment and express higher basal levels
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of SRSF1. By contrast, SRSF6 was strongly upregulated in DR-
PANC-1 but slightly reduced in DR-Pt45P1 (Supplementary Figure
S5B). Thus, upregulation of PTBP1 appears to specifically correlate
with the regulation of PKM2 splicing in DR-PDAC cells.
PTBP1 binds in vivo PKM intron 8 and its downregulation impairs
PKM2 expression and sensitizes DR-PDAC cells to drug-induced
cell death
To test whether PTBP1 was recruited to the PKM transcript more
efficiently in DR-PDAC cells, we analyzed in vivo binding by UV-
crosslinked and RNA immunoprecipitation (CLIP) assays in PCL-
and DR-Pt45P1 cells, silenced or not for PTBP1 (Figure 6a). Binding
of PTBP1 in intron 8 of PKM favors skipping of exon 9 in the
mature transcript,35 thereby generating the PKM2 isoform. Thus,
we analyzed two regions in intron 8, named A and B (Figure 6a),
which were identified as high PTBP1-bound sequences by CLIP
sequencing analysis.41 CLIP assays showed that PTBP1 was
recruited more efficiently to PKM intron 8 in DR-Pt45P1 cells with
respect to PCL-Pt45P1 cells (Figure 6a). Increased binding was
specific and likely dependent on the higher expression of PTBP1 in
DR cells, as it was suppressed by knockdown of the protein to
levels comparable with those expressed in PCL cells (Figure 6a).
Thus, upregulation of PTBP1 in DR-PDAC cells leads to increased
recruitment of this splicing factor to PKM intron 8.
To evaluate the contribution of PTBP1 to the regulation of the
PKM2 variant, we analyzed PKM AS in DR-PDAC cells knocked
down for PTBP1. Knockdown of endogenous PTBP1 increased
PKM1 splicing in DR-PDAC cells, resulting in a switch in PKM1 and
PKM2 protein levels (Figure 6b). These results confirm that
upregulation of PTBP1 promotes PKM2 splicing in DR-PDAC cells.
To test whether PTBP1 affected additional splicing events in DR-
PDAC cells, we analyzed a subset of genes whose AS is regulated
by this splicing factor in other cell types.41–43 RT–PCR analysis
indicated that only the FGFR2 IIIc variant correlated with the
higher expression of PTBP1 in both DR-PDAC cell lines
(Supplementary Figure S6A). However, silencing of PTBP1 did
not affect this splicing event (Supplementary Figure S6E),
indicating that expression of FGFR2 IIIc correlates with but is not
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analyses were performed by the paired Student’s t-test (**P⩽ 0.01; ns, not significant). PTBP1 silencing in DR-Pt45P1 cells and IP efficiency
were assessed by western blot analysis. (b) RT–PCR and western blot analyses to evaluate PKM1 and PKM2 expression in DR-PDAC cells
transfected with either ctrl or PTBP1 siRNAs. Bar graphs represent the percentage of PKM2 variant, as assessed by densitometric analysis of the
bands. Statistical analyses were performed by the paired Student’s t-test comparing the values of DR-PDAC cells transfected with si-ctrl with
those obtained in DR-PDAC cell transfected with si-PTBP1 siRNA (**P⩽ 0.01; upper panels: mean± s.d., n= 3, **P⩽ 0.01). (b) PTBP1 silencing
was assessed by western blot analysis. Coomassie staining was used as loading control. (c and d) Western blot analyses assessing PTBP1
expression levels in PCL- and DR-Pt45P1 or PANC-1 PDAC cells transfected with ctrl or PTBP1 siRNAs. Coomassie staining was used as loading
control. (c and d) Bar graphs show the percentage of cell death from three experiments (mean± s.d.) as assessed by immunofluorescence
analysis of the cleaved form of caspase-3 in PCL-, DR-PDAC cells described in c and d, and treated as indicated for 72 h. Statistical analyses
were performed by the paired Student’s t-test comparing DR-PDAC cell values with those obtained in PCL-PDAC cells treated with
gemcitabine, whereas brackets indicate statistical comparison of the indicated samples (**P⩽ 0.01; ns, not significant).
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dependent on high PTBP1 expression in DR-PDAC cells. By
contrast, splicing of EZH2, CTTN, RASSF8, MINK1, EIF4G2, FAM38A,
CCDC138 and TPM1 was either similar in PCL- and DR-PDAC cells
or altered in one of the two DR cell lines (Supplementary Figures
S6A–C). These findings indicate that splicing of PKM is specifically
modulated by PTBP1 overexpression in DR-PDAC cells.
To investigate whether PTBP1 expression is required for the
resistance of DR-PDAC to chemotherapeutic treatments, we
analyzed gemcitabine-induced cell death in PTBP1-depleted DR-
PDAC cells. Downregulation of PTBP1 expression significantly
rescued the sensitivity of DR-PDAC cells to treatment with
gemcitabine, reaching levels of cell death similar to those of
PCL-PDAC cells (Figures 6c and d). We also tested resistance
to cisplatin as prototype of a class of drugs currently used in
clinical trials of combined chemotherapy for advanced PDAC.44
Cell death analysis showed that DR-PDAC cells were more
resistant to cisplatin treatment than PCL-PDAC cells (Supplementary
Figure S7A). However, switching PKM splicing by either ASO
transfection (Supplementary Figure S7B) or knockdown of PTBP1
(Supplementary Figure S6C) rescued sensitivity to cisplatin,
suggesting that the PTBP1/PKM2 axis is involved in PDAC cell
survival to multiple cytotoxic drugs.
Collectively, these results indicate that high PTBP1 expression
levels are required for the maintenance of the DR phenotype of
PDAC cells and suggest that this splicing factor mainly confers
drug resistance to PDAC cells through the promotion of PKM2
splicing.
DISCUSSION
PDAC is a human cancer characterized by very poor prognosis.
Chemotherapeutic approaches are largely ineffective and treat-
ment with the elective agent gemcitabine slightly improves
survival in patients with advanced disease, but does not represent
a cure.1 For this reason, understanding the biology of PDAC cells
might shed light on novel therapeutic strategies for the manage-
ment of advanced PDAC. In this work, we show that chronic
gemcitabine treatment leads to isolation of DR-PDAC cells that
display higher resistance not only to gemcitabine, but also to
cisplatin, a prototype of cytotoxic drugs largely used in human
cancer therapy, including PDAC.44 These findings suggest that
hostile stimuli promote the adaptive capabilities of PDAC cells,
thus favoring the selection of DR populations.
In order to elucidate the molecular mechanisms involved in the
acquisition of the DR phenotype by PDAC cells we focused on AS
regulation, because this process is emerging as a key determinant
of eukaryotic cell plasticity45 that is often altered in human
cancers.5–8 Furthermore, genotoxic stresses such as those
imposed by chemotherapeutic treatments can finely tune the
expression of splice variants that protect cancer cells.15 In this
regard, our study identifies PKM splicing as a novel contributor to
drug resistance acquired by PDAC cells during chronic chemother-
apeutic treatment. We found that promotion of PKM2 is the AS
event that correlates more closely with drug resistance among a
subset of cancer-relevant splicing events analyzed. Importantly,
PKM2 splicing and expression are functionally relevant for the
resistance to chemotherapeutic treatment, as switching splicing
toward PKM1 by ASO transfection restored sensitivity of DR-PDAC
cells to both gemcitabine and cisplatin. These results point to
PKM2 as a new potential prognostic marker and therapeutic target
for PDAC. In support of this hypothesis, we also found that high
PKM2 expression was the only risk factor significantly associated
with shorter RFS in patients receiving radical surgery and adjuvant
chemotherapy with gemcitabine. These results suggest that
increased PKM2 expression might be responsible for lower
response of residual cancer cells to chemotherapy. Although we
did not find a significant correlation between PKM2 expression
and overall survival, the observed trend suggests that patients
expressing higher PKM2 levels also have a shorter survival rate
(Supplementary Table S1). Studies with a larger cohort of patients
will be required to further assess whether or not PKM2 can be
used as marker for prediction of severity of the disease and
response to treatments.
The role of PKM2 in cancer is not fully elucidated yet.
Nevertheless, several observations pointed out that this splice
variant is expressed at higher levels in cancer tissues versus their
normal counterparts.22,35 PKM2 protein was proposed as a
potential molecular marker of PDAC, as immune reactivity toward
this isoform was elevated in the blood from patients and positively
correlated with metastatic disease.46 We now show that PKM2 is
barely detectable in areas of the pancreas with normal glands,
whereas its expression is increased in neoplastic lesions. Moreover,
our findings document that upregulation of PKM2 in DR-PDAC
cells is required for survival in the presence of gemcitabine or
cisplatin. Notably, depletion of PKM2 in several human cancer cell
lines caused apoptosis even in the absence of chemotherapeutic
treatments.38,39 This effect was cancer specific, as depletion of
PKM2 in non-cancerous cells did not affect their viability.39 In the
case of DR-PDAC cells, however, depletion of endogenous PKM2
per se does not trigger cell death, indicating that PDAC cells are
somewhat less dependent on this enzyme for viability. Never-
theless, PKM2 was strictly necessary to withstand genotoxic stress
in DR-PDAC cells. Importantly, PKM2 expression has been linked to
response to chemotherapy also in lung cancer, as its depletion
sensitized to apoptosis triggered by chemotherapeutic treatment
in mouse xenograft models.47 Our work also supports this scenario
and suggests that modulation of PKM splicing by ASO treatment is
a potential therapeutic tool to increase the efficacy of standard
chemotherapy in advanced PDAC. This strategy might represent a
promising approach, as ASOs are already in clinical trials for other
splicing-caused diseases and improvement of their design and
administration protocols might insure their use in cancer therapy
in the near future.40
Aberrant expression of several splicing factors correlates with
cancer onset, progression and/or response to therapeutic
treatments.48 Our findings indicate that the switch in PKM AS
correlates with the upregulation of PTBP1 in DR-PDAC cells. A role
for PTBP1 in PKM splicing was already shown in glioblastoma,
where this splicing factor acted in concert with hnRNP A1 and
A2/B1 to promote PKM2 splicing.35 However, we found that
neither of these hnRNPs was consistently modulated in DR-PDAC
cells. Moreover, knockdown of PTBP1 to mimic the levels observed
in PCL-PDAC cells was sufficient to raise PKM1 levels to those
present in parental cells. Thus, PTBP1 is the main factor in the
regulation of PKM AS during the acquisition of the DR phenotype
by PDAC cells. Importantly, the effect of PTBP1 on PKM2 splicing in
PDAC cells appears to be direct, as it correlates with the extent of
PTBP1 recruitment to PKM intron 8. Furthermore, its effect on PKM
AS can account for the acquired resistance to genotoxic drugs, as
DR-PDAC cells knocked down for PTBP1 switched AS in favor of
PKM1 and became sensitive to gemcitabine and cisplatin such as
PCL-PDAC cells. Although the pro-survival effect of PTBP1
upregulation in PDAC cells might also involve other targets of
this splicing factor, our observations suggest that splicing of PKM2
represents the main factor. Indeed, by monitoring a group of
splice variants previously shown to be the target of PTBP1 in other
cellular systems,41,42,43 we did not observe striking and consistent
changes correlating with the DR-PDAC phenotype. The only
relevant change observed was promotion of the FGFR2 IIIc variant,
which, however, was unaffected by knockdown of PTBP1 in DR-
PDAC cells. Furthermore, selectively restoring the PCL pattern of
PKM splicing by ASO transfection almost completely rescued the
sensitivity of DR-PDAC cells to genotoxic stresses. Thus, our results
suggest that PKM AS is particularly sensitive to changes in the
expression levels of PTBP1 in PDAC cells, and that this splicing
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event represent a key resource for these cells to acquire drug
resistance.
In conclusion, our work characterizes a novel PTBP1/PKM2 pro-
survival pathway triggered by chronic treatment of PDAC cells
with gemcitabine. Interfering with this axis by repressing PKM2
splicing or PTPB1 expression can restore sensitivity of DR-PDAC
cells to drug treatment. As development of therapeutic ASOs is
already a clinical approach for other human diseases,40 these
findings might represent a promising strategy to improve
therapeutic approaches for PDAC and to impact the resistance
of cancer cells to current treatments.
MATERIALS AND METHODS
Cell culture, treatments and transfections
Pt45P1 and PANC-1 cells were obtained from the Centre for Molecular
Oncology, Barts Cancer Institute (London, UK) in 2004 and authenticated in
2012. DR cells were obtained by treating PCL with 10 μM gemcitabine
continuously for 7 days (medium replaced every 72 h) and then released in
normal medium for 15 days. Resistant clones were pooled, amplified and
cultured by performing a 24-h pulse of 10 μM gemcitabine every other
week, to maintain selection. PCL and DR cells were maintained in RPMI
1640 (Lonza, Basel, Switzerland) supplemented with 10% fetal bovine
serum, gentamycin, penicillin and streptomycin. Gemcitabine (Eli Lilly &
Company, Indianapolis, IN, USA) and cisplatin (Sigma-Aldrich, St Louis, MO,
USA) were dissolved in water. For ASO transfection, cells were transduced
by scraping delivery according to the manufacturer’s instructions (Gene
Tools, Philomath, OR, USA) with PKM2 or control ASO (10 μM for DR-PANC-1
cells and 15 μM for DR-Pt45P1 cells). For RNA interference, cells were
transfected twice with 30 nM PTBP1 small interfering RNAs (On target
plus human PTBP1 5725 siRNA, Dharmacon, Lafayette, CO, USA) using
Lipofectamine RNAiMAX and Opti-MEM medium (Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s instructions.
Colony formation assay and cell death analyses
Single-cell suspensions were plated in 6-well plates (500 cells/plate for
Pt45P1, 750 cells/plate for PANC-1). After 1 day, cells were treated for
24 h with gemcitabine. Fresh medium was replaced every 48 h. After
10–12 days, cells were fixed in methanol for 10min, stained overnight with
5% Giemsa (Sigma-Aldrich), washed in phosphate-buffered saline and
dried. Pictures were taken using a digital camera and colonies were
counted. For cell death analyses, cells were seeded at 70% confluence and
treated as described for 72 h. Cells were then washed in phosphate-
buffered saline and either trypsinized and incubated with 0.4% Trypan
Blue Stain (Sigma-Aldrich) or processed for caspase-3 immunofluorescence
using anti-cleaved caspase-3 antibody (1:500; Sigma-Aldrich) as previously
described.31,49 Positive cells were then counted using the Thoma’s
chamber (Trypan blue) or fluorescence microscopy (caspase-3). Five
random fields were chosen for each treatment and at least 200 cells/
field were counted.
PCR analyses
RNA was extracted using TRIzol (Life Technologies) according to the
manufacturer’s instructions. After digestion with RNase-free DNase (Life
Technologies), 1 μg of total RNA was retrotranscribed using M-MLV reverse
transcriptase (Promega, Madison, WI, USA), used as template for
conventional PCR reactions (GoTaq, Promega). Products were analysed
on agarose or acrylamide gels. RT–PCR images were collected with Biorad
Universal Hood II using Image Lab software (Bio-Rad Laboratories,
Hercules, CA, USA). Real-time quantitative PCR analysis was performed
using LightCycler 480 SYBR Green I Master and the LightCycler 480 System
(Roche, Mannheim, Germany), according to the manufacturer’s instruc-
tions. Primers used are listed in Supplementary Table S2.
Protein extracts and western blot analysis
Cells were resuspended in RIPA buffer: 150 mM sodium chloride, 1.0%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 1 mM
dithiothreitol, 0.5 mM NaVO4 and protease inhibitor cocktail (Sigma-
Aldrich). After 10 min on ice, extracts were centrifuged for 10min at
12 000 g and supernatants were collected and used for western blotting as
described.49 Primary antibody incubation (1:1000) was carried out with the
following antibodies: PKM1, hnRNPA1, hnRNPA2/B1 and hnRNPC1/C2
(Sigma-Aldrich); PKM2 (Cell Signaling Technology, Danvers, MA, USA);
PTBP1, SRSF1, SRP20 and SRp40/p55/p75 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA); hnRNPF/H (Abcam, Cambridge, UK). PTBP2 antibody was a
generous gift of Professor Douglas L Black (UCLA, Los Angeles, CA, USA).
Images of the western blotting were acquired as TIFF files.
IHC analysis
IHC was performed as previously described.31 Briefly, formalin-fixed,
paraffin-embedded tissue samples obtained from 42 primary non-
metastatic PDAC patients receiving surgery with radical intent were
investigated for PKM2 expression, on informed consent. All patients
received gemcitabine-based adjuvant therapy after surgery. Clinical and
histopathological data, time of tumor recurrence and survival for each
patient were recorded. IHC was performed on 4-μm-thick sections. Antigen
retrieval was carried out with EDTA at pH 8 (60min at room temperature).
Staining was carried out using anti PKM2 antibody (1:1600, Cell Signaling
Technology), visualized by Envision-Flex (Dako, Glostrup, Denmark).
Staining of PKM2 in neoplastic cells was scored based on distribution
and intensity. Distribution was scored as 0 (0%), 1 (1%–50%) and 2 (51%–
100%). Intensity was scored as 0 (no signal), 1 (mild), 2 (intermediate) and 3
(strong). Values were summed in a total score from 0 to 5. Samples were
classified as ‘low PKM2’ expression (score ⩽ 3) and as ‘high PKM2’
expression (score 43). Statistical analysis was performed by MedCalc 9.6
(www.medcalc.be). Differences for continuous variables were evaluated by
t-test and for categorical variables by Fisher’s test. Analysis of RFS and of
overall survival was performed by Kaplan–Meier method and analysed by
log-rank test. Univariate and multivariate analyses for risk factors affecting
survival were performed by Cox-proportional hazards regression model
test; a P-value o0.05 was considered as statistically significant
(Supplementary Table S1). Images were taken from a Zeiss axioskop 2
plus and elaborate with software Zeiss axiovision (Carl Zeiss Microscopy,
Oberkochen, Germany).
CLIP assays
For CLIP assays, cell extractions were performed as previously
described.50,51 Half extract (1 mg) was treated with proteinase K for
30min at 37 °C and RNA was purified (input). The remaining half (1 mg)
was diluted to 1ml with lysis buffer and immunoprecipitated by using anti-
PTBP1 (Santa Cruz Biotechnology) antibody or IgGs (negative control), in
the presence of protein-G magnetic dynabeads (Life Technologies). RNaseI
1:1000 (10 μl/ml; Life Technologies) were added. After immunoprecipita-
tion and washes,50,51 an aliquot (10%) of the sample was kept as control of
immunoprecipitation, while the rest was treated with 50 μg of proteinase K
and incubated for 1 h at 55 °C. RNA was then isolated.
Image acquisition and manipulation
Images in Figure 1b were taken from an inverted microscope (IX70;
Olympus, Shinjuku, Tokyo, Japan) using an LCA ch 40× /0.60 objective.
Adobe Photoshop and Illustrator (Adobe System, San Jose, CA, USA) were
used for composing the panels.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
We thank Andrea D’Ascenzo and Enrico Duranti for help with immunohistochemistry;
Dr Chiara Naro for helpful suggestions throughout the study; and Dr Vittoria Pagliarini
for critical reading of the manuscript. This work was supported by Association for
International Cancer Research (AICR) (grant 12-0150), Associazione Italiana Ricerca sul
Cancro (AIRC) (grant 14581) and Fondazione Santa Lucia Ricerca Corrente.
AUTHOR CONTRIBUTIONS
SC, PB and IP performed the experiments and analyzed the data. EP and VF
performed IHC experiments and score analysis. GC performed statistical analysis
of patients; SC, GDF, GC and CS wrote the manuscript. SC and CS designed
the study.
Role of PKM2 and PTBP1 in PDAC drug resistance
S Calabretta et al
8
Oncogene (2015), 1 – 9 © 2015 Macmillan Publishers Limited
REFERENCES
1 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and
future challenges. Nat Rev Clin Oncol 2010; 7: 163–1672.
2 Michl P, Gress TM. Current concepts and novel targets in advanced
pancreatic cancer. Gut 2013; 62: 317–326.
3 Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605–1617.
4 Tang SC, Chen YC. Novel therapeutic targets for pancreatic cancer. World J
Gastroenterol 2014; 20: 10825–10844.
5 David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways
and programs unhinged. Genes Dev 2010; 24: 2343–2364.
6 Zhang J, Manley JL. Misregulation of pre-mRNA alternative splicing in cancer.
Cancer Discov 2013; 3: 1228–1237.
7 Bonomi S, Gallo S, Catillo M, Pignataro D, Biamonti G, Ghigna C. Oncogenic
alternative splicing switches: role in cancer progression and prospects for therapy.
Int J Cell Biol 2013; 2013: 962038.
8 Sette C, Ladomery M, Ghigna C. Alternative splicing: role in cancer development
and progression. Int J Cell Biol 2013; 2013: 421606.
9 Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009; 136: 777–793.
10 Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM et al.
Cell motility is controlled by SF2/ASF through alternative splicing of the Ron
protooncogene. Mol Cell. 2005; 20: 881–890.
11 Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding
the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14:
185–193.
12 Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L et al. Cancer-
associated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16: 670–676.
13 Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, Comstock C et al.
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-
binding protein Sam68. Cancer Res 2010; 70: 229–239.
14 Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q et al. BCLAF1 and its splicing regulator
SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun
2014; 5: 4581.
15 Dutertre M, Sanchez G, Barbier J, Corcos L, Auboeuf D. The emerging role of pre-
messenger RNA splicing in stress responses: sending alternative messages and
silent messengers. RNA Biol 2011; 8: 740–747.
16 Busà R, Geremia R, Sette C. Genotoxic stress causes the accumulation of the
splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin.
Nucleic Acids Res 2010; 38: 3005–3018.
17 Paronetto MP, Miñana B, Valcárcel J. The Ewing sarcoma protein regulates DNA
damage-induced alternative splicing. Mol Cell 2011; 43: 353–368.
18 Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression
is associated with tumorigenic imbalance in mitogen-activated protein kinase
pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007; 67:
2072–2080.
19 Naro C, Sette C. Phosphorylation-mediated regulation of alternative splicing
in cancer. Int J Cell Biol 2013; 2013: 151839.
20 Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI et al.WT1
mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF
splicing. Cancer Cell. 2011; 20: 768–780.
21 Omenn GS, Yocum AK, Menon R. Alternative splice variants, a new class of protein
cancer biomarker candidates: findings in pancreatic cancer and breast cancer
with systems biology implications. Dis Markers 2010; 28: 241–251.
22 Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R
et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism
and tumour growth. Nature 2008; 452: 230–233.
23 Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D et al. PKM2 phosphorylates histone
H3 and promotes gene transcription and tumorigenesis. Cell 2012; 150: 685–696.
24 Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L et al. EGFR-induced and PKCε
monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression
and promotes tumorigenesis. Mol Cell 2012; 48: 771–784.
25 Shultz JC, Goehe RW, Murudkar CS, Wijesinghe DS, Mayton EK, Massiello A et al.
SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing
enhancer affecting the chemotherapeutic sensitivity of non-small cell lung
cancer cells. Mol Cancer Res 2011; 9: 889–900.
26 Droin N, Rébé C, Bichat F, Hammann A, Bertrand R, Solary E. Modulation
of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin
condensation, apoptotic body formation and phosphatidylserine externalization.
Oncogene 2001; 20: 260–269.
27 Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift
of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002; 277:
49374–49382.
28 Anczuków O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R et al. The
splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary
epithelial cell transformation. Nat Struct Mol Biol 2012; 19: 220–228.
29 Proussakova OV, Rabaya NA, Moshnikova AB, Telegina ES, Turanov A, Nanazashvili MG
et al. Oligomerization of soluble Fas antigen induces its cytotoxicity. J Biol Chem
2003 Sep; 278: 36236–36241.
30 Nakajima S, Lan L, Wei L, Hsieh CL, Rapić-Otrin V, Yasui A et al. Ubiquitin-specific
protease 5 is required for the efficient repair of DNA double-strand breaks. PLoS
One 2014; 9: e84899.
31 Adesso L, Calabretta S, Barbagallo F, Capurso G, Pilozzi E, Geremia R et al.
Gemcitabine triggers a pro-survival response in pancreatic cancer cells
through activation of the MNK2/eIF4E pathway. Oncogene 2013; 32:
2848–2857.
32 Maimon A, Mogilevsky M, Shilo A, Golan-Gerstl R, Obiedat A, Ben-Hur V et al.
Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts
Ras-induced transformation. Cell Rep 2014; 7: 501–513.
33 Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for
cancer and stem cells. Nat Rev Cancer 2006; 6: 637–645.
34 Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H et al. Alternatively
spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner.
Oncogene 1998; 16: 1701–1712.
35 David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by
c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463:
364–368.
36 Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring
benefits on cancer cells. Clin Cancer Res 2012; 18: 5554–5561.
37 Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y et al. PKM2 regulates chromo-
some segregation and mitosis progression of tumor cells. Mol Cell. 2014; 53:
75–87.
38 Wang Z, Jeon HY, Rigo F, Bennett CF, Krainer AR. Manipulation of PK-M mutually
exclusive alternative splicing by antisense oligonucleotides. Open Biol 2012; 2:
120133.
39 Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and
tumor regression. J Exp Med 2012; 209: 217–224.
40 Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and
antisense oligonucleotides. Nat Rev Drug Discov 2012; 11: 125–140.
41 Xue Y, Zhou Y, Wu T, Zhu T, Ji X, Kwon YS et al. Genome-wide analysis of PTB-RNA
interactions reveals a strategy used by the general splicing repressor to modulate
exon inclusion or skipping. Mol Cell 2009; 36: 996–1006.
42 Carstens RP, Wagner EJ, Garcia-Blanco MA. An intronic splicing silencer
causes skipping of the IIIb exon of fibroblast growth factor receptor 2 through
involvement of polypyrimidine tract binding protein. Mol Cell Biol 2000; 20:
7388–7400.
43 Llorian M, Schwartz S, Clark TA, Hollander D, Tan LY, Spellman R et al.
Position-dependent alternative splicing activity revealed by global profiling of
alternative splicing events regulated by PTB. Nat Struct Mol Biol 2010; 17:
1114–1123.
44 Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C et al. Phase I trial
of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New
Drugs 2014; 32: 710–716.
45 Braunschweig U, Gueroussov S, Plocik AM, Graveley BR, Blencowe BJ. Dynamic
integration of splicing within gene regulatory pathways. Cell 2013; 152:
1252–1269.
46 Cerwenka H, Aigner R, Bacher H, Werkgartner G, el-Shabrawi A, Quehenberger F
et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with
benign, malignant and metastasizing pancreatic lesions. Anticancer Res 1999; 19:
849–851.
47 Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL et al. Silencing of pkm2
increases the efficacy of docetaxel in human lung cancer xenografts in mice.
Cancer Sci 2010; 101: 1447–1453.
48 Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors
in cancer. EMBO Rep 2008; 9: 1087–1093.
49 Paronetto MP, Achsel T, Massiello A, Chalfant CE, Sette C. The RNA-binding
protein Sam68 modulates the alternative splicing of Bcl-x. J Cell Biol 2007; 176:
929–939.
50 Bielli P, Busà R, Di Stasi SM, Munoz MJ, Botti F, Kornblihtt AR et al. The tran-
scription factor FBI-1 inhibits SAM68-mediated BCL-X alternative splicing and
apoptosis. EMBO Rep 2014; 15: 419–427.
51 Bielli P, Bordi M, Di Biasio V, Sette C. Regulation of BCL-X splicing reveals a role for
the Polypyrimidine-tract binding protein (PTBP1/hnRNP I) in alternative 5 ‘splice
site selection. Nucleic Acids Res 2014; 42: 12070–12081.
Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)
Role of PKM2 and PTBP1 in PDAC drug resistance
S Calabretta et al
9
© 2015 Macmillan Publishers Limited Oncogene (2015), 1 – 9
